IGF-I R/IGF1R was detected in perfusion fixed paraffin-embedded sections of mouse heart using Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) at 15 µg/mL for 1 hour at room temperature ...read more
Western blot shows lysates of NTera‑2 human testicular embryonic carcinoma cell line, SK‑Mel‑28 human malignant melanoma cell line, and G361 human melanoma cell line. PVDF membrane was probed with 1 µg/mL of ...read more
MCF‑7 human breast cancer cell line was stained with Mouse Anti-Human IGF‑I R/IGF1R Monoclonal Antibody (Catalog # MAB391, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) ...read more
IGF-I R/IGF1R was detected in immersion fixed MCF‑7 human breast cancer cell line (positive staining; left panel) and HDLM human Hodgkin's lymphoma cell line (negative staining; right panel) using Mouse ...read more
Recombinant Human (rh) IGF‑I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by rhIGF‑I/IGF-1 (6 ng/mL) ...read more
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IGF-I R/IGF1R Glu31-Asn932 Accession # P08069
Detects human IGF-I R/IGF1R in sandwich ELISAs and Western blots. Detects mouse IGF-I R/IGF1R in Immunohistochemistry. In sandwich immunoassays, less than 0.15% cross-reactivity or interference was observed with recombinant human (rh) IGF-I, rhIGF‑II, rhIL‑3 R alpha, rhIL‑9 R, and rhTGF‑ beta RII.
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for IGF-I R/IGF1R Antibody (33255) [Unconjugated]
insulin-like growth factor 1 receptor
Insulin-like growth factor I receptor
soluble IGF1R variant 1
soluble IGF1R variant 2
Insulin-like growth factor I receptor (IGF-I R) is a disulfide-linked heterotetrameric transmembrane protein consisting of two alpha and two beta subunits. Both the alpha and beta subunits are encoded within a single receptor precursor cDNA. The proreceptor polypeptide is proteolytically cleaved and disulfide-linked to yield the mature heterotetrameric receptor. The alpha subunit of IGF-I R is extracellular while the beta subunit has an extracellular domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain. IGF-I R is highly expressed in all cell types and tissues. Essentially all of the biological activities of IGF-I and -II have been shown to be mediated via IGF-I R.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our IGF-I R/IGF1R Antibody (33255) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.